Álex Herrera on Muck Rack

Álex Herrera

Madrid
As seen in: 20 Minutos, MSN España, Nature, Wiley Online Library, Medscape, KING-TV (Seattle, WA), KHOU-TV (Houston, TX), The Lancet, WKYC-TV (Cleveland, OH), WXIA-TV (Atlanta, GA), WFAA-TV (Dallas, TX) and
Subdirector - 20minutos. En las montañas. 🏔️
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Álex

Contact Álex, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dr Chari on Navigating CAR T, Bispecifics, and Other Treatment Approaches in R/R Myeloma

|
By Kelly E McCann, Alex Herrera, Álex Herrera, Rena D. Callahan
| OncLive
BCMA[-directed therapy] is beating SOC, and that’s a big message to get across. Ajai Chari, MD, a professor of medicine and director of the Multiple Myeloma Program at the University of California, San Francisco, detailed treatment navigation in relapsed/refractory multiple myeloma in the era of CAR T-cell therapies and bispecific antibodies, as discussed by experts during the 2026 Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Meeting.
Open in Who Shared Issue with article?

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma Original

|
By Karan L. Chohan, James Godfrey, Lorenzo Falchi, Manali K. Kamdar, Ajay Major, Wendy O. Dixon, Jennifer Crombie, Reid W. Merryman, Gilles Salles, Amy Ayers, Ayushi Chauhan, Alex Herrera, Álex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha, Rina L. Welkie, Steven Bair, Sonia Godbole, Omnia Farahat
| Nature
Dear Editor, Despite recent advances in the treatment of systemic aggressive B-cell non-Hodgkin lymphomas (B-NHL), central nervous system (CNS) involvement remains a therapeutic challenge and is associated with dismal outcomes [1]. Chimeric antigen receptor (CAR) T-cell therapy achieves high overall response rates (ORR) in patients with CNS involvement, but responses are often short-lived (1-year progression-free survival (PFS) of 16–48%) [2,3,4,5].
Open in Who Shared View Duplicates (2) Issue with article?

Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC

|
By Jonathan Lee, Alex Herrera, Álex Herrera, Alexander B. Olawaiye
| OncLive
“[This approval] is clinically very impactful because [ROSELLA] used relacorilant and nab-paclitaxel in a non–biomarker-selected population. There was no testing required for patients to participate in the trial if they met all the other inclusion criteria.” Alexander B.
Open in Who Shared Issue with article?
See all 327 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Álex

Contact Álex, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified